What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10.

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $425.00 ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a market cap of $14.28 billion, a price-to-earnings ratio of 13.96, a PEG ratio of 0.97 and a beta ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...